Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 45,910 shares, a growth of 55.9% from the July 15th total of 29,440 shares. Based on an average trading volume of 25,260 shares, the short-interest ratio is currently 1.8 days. Currently, 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rangeley Capital LLC boosted its stake in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Barinthus Biotherapeutics by 115.8% in the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares during the last quarter. Finally, Baird Financial Group Inc. increased its position in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Stock Performance

NASDAQ:BRNS opened at $0.59 on Tuesday. Barinthus Biotherapeutics has a one year low of $0.51 and a one year high of $1.83. The firm has a market cap of $24.24 million, a P/E ratio of -0.58 and a beta of -0.39. The firm has a 50-day simple moving average of $0.63 and a 200-day simple moving average of $0.64.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.